Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease

Abstract

A pneumostoma management device for maintaining the patency of a pneumostoma while controlling the flow of gases and discharge through the pneumostoma. The pneumostoma management device includes a bulb connected to a tube which enters the pneumostoma. A flow control device regulates air flow in and out of the pneumostoma via the tube. A hydrophobic filter traps discharge in the bulb while allowing gases to escape.

Description

BACKGROUND OF THE INVENTION

In the United States alone, approximately 14 million people suffer from some form of chronic obstructive pulmonary disease. However an additional ten million adults have evidence of impaired lung function indicating that COPD may be significantly underdiagnosed. The cost of COPD to the nation in 2002 was estimated to be $32.1 billion. Medicare expenses for COPD beneficiaries were nearly 2.5 times that of the expenditures for all other patients. Direct medical services accounted for $18.0 billion, and indirect cost of morbidity and premature mortality was $14.1 billion (FIG. 11). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020.

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease of the airways that is characterized by a gradual loss of lung function. In the United States, the term COPD includes chronic bronchitis, chronic obstructive bronchitis, and emphysema, or combinations of these conditions. In emphysema the alveoli walls of the lung tissue are progressively weakened and lose their elastic recoil. The breakdown of lung tissue causes progressive loss of elastic recoil and the loss of radial support of the airways which traps residual air in the lung. This increases the work of exhaling and leads to hyperinflation of the lung. When the lungs become hyperinflated, forced expiration cannot reduce the residual volume of the lungs because the force exerted to empty the lungs collapses the small airways and blocks air from being exhaled. As the disease progresses, the inspiratory capacity and air exchange surface area of the lungs is reduced until air exchange becomes seriously impaired and the individual can only take short shallow labored breaths (dyspnea).

The symptoms of COPD can range from the chronic cough and sputum production of chronic bronchitis to the severe disabling shortness of breath of emphysema. In some individuals, chronic cough and sputum production are the first signs that they are at risk for developing the airflow obstruction and shortness of breath characteristic of COPD. With continued exposure to cigarettes or noxious particles, the disease progresses and individuals with COPD increasingly lose their ability to breathe. Acute infections or certain weather conditions may temporarily worsen symptoms (exacerbations), occasionally where hospitalization may be required. In others, shortness of breath may be the first indication of the disease. The diagnosis of COPD is confirmed by the presence of airway obstruction on testing with spirometry. Ultimately, severe emphysema may lead to severe dyspnea, severe limitation of daily activities, illness and death.

There is no cure for COPD or pulmonary emphysema, only various treatments, for ameliorating the symptoms. The goal of current treatments is to help people live with the disease more comfortably and to prevent the progression of the disease. The current options include: self-care (e.g., quitting smoking), medications (such as bronchodilators which do not address emphysema physiology), long-term oxygen therapy, and surgery (lung transplantation and lung volume reduction surgery). Lung volume reduction surgery is an invasive procedure primarily for patients who have a localized (heterogeneous) version of emphysema; in which, the most diseased area of the lung is surgically removed to allow the remaining tissue to work more efficiently. Patients with diffuse emphysema cannot be treated with LVRS, and typically only have lung transplantation as an end-stage option. However, many patients are not candidates for such a taxing procedure.

A number of less-invasive surgical methods have been proposed for ameliorating the symptoms of COPD. In one approach new windows are opened inside the lung to allow air to more easily escape from the diseased tissue into the natural airways. These windows are kept open with permanently implanted stents. Other approaches attempt to seal off and shrink portions of the hyperinflated lung using chemical treatments and/or implantable plugs. However, these proposals remain significantly invasive and have unproven efficacy. None of the surgical approaches to treatment of COPD has been widely adopted. Therefore, a large unmet need remains for a medical procedure that can sufficiently alleviate the debilitating effects of COPD and emphysema.

SUMMARY OF THE INVENTION

In view of the disadvantages of the state of the art, Applicants have developed a method for treating COPD in which an artificial passageway is made through the chest wall into the lung. An anastomosis is formed between the artificial passageway and the lung by creating a pleurodesis between the visceral and parietal membranes surrounding the passageway as it enters the lung. The pleurodesis prevents air from entering the pleural cavity and causing a pneumothorax (deflation of the lung due to air pressure in the pleural cavity). The pleurodesis is stabilized by a fibrotic healing response between the membranes. The artificial passageway through the chest wall also becomes epithelialized. The result is a stable artificial aperture through the chest wall which communicates with the parenchymal tissue of the lung.

The artificial aperture into the lung through the chest is referred to herein as a pneumostoma. The pneumostoma provides an extra pathway that allows air to exit the lungs while bypassing the natural airways which have been impaired by COPD and emphysema. By providing this ventilation bypass, the pneumostoma allows the stale air trapped in the lung to escape from the lung. By shrinking the lung, the ventilation bypass allows more fresh air to be drawn in through the natural airway and increases the effectiveness of all of the tissues of the lung. Increasing the effectiveness of gas exchange allows for increased absorption of oxygen into the bloodstream and also increased removal of carbon dioxide. Reducing the amount of carbon dioxide retained in the lung reduces hypercapnia which also reduces dyspnea. The pneumostoma thereby achieves the advantages of lung volume reduction surgery without surgically removing a portion of the lung or sealing off a portion of the lung.

In accordance with an embodiment of the present invention a partially-implantable pneumostoma management device is provided which can be placed into a pneumostoma to prevent the entry of foreign substances into the lung, control air flow through the pneumostoma and collect any materials that may exit the lung.

In accordance with another embodiment of the present invention a pneumostoma management device is provided with a hydrophobic filter element. The pneumostoma management device includes a hydrophobic filter to prevent the entry of water into the device and pneumostoma.

In accordance with another embodiment of the present invention a pneumostoma management device is provided with a flow-control device. The flow-control device permits air to flow out of the pneumostoma but inhibits the flow of air into the pneumostoma.

In accordance with another embodiment of the present invention a pneumostoma management device is provided with an integral trap chamber. The integral trap system for collecting any liquid or particulate matter which may be emitted through the pneumostoma.

In accordance with another embodiment of the present invention a method for controlling entry and exit of material through a pneumostoma is provided in which the disclosed pneumostoma management device is temporarily implanted in a pneumostoma.

In accordance with a particular embodiment of the present invention, a pneumostoma management device is configured to be mounted on a chest of a patient to treat a lung of a patient and control the flow of liquids and gases through a pneumostoma. The pneumostoma management device includes a tube adapted to pass into the pneumostoma wherein the tube has a distal opening adapted to be positioned within the lung to allow liquids and gases to enter the tube from the lung. The pneumostoma management device also includes a bulb connected to a proximal end of the tube wherein the bulb defines a chamber. A one-way valve is positioned between the distal opening of the tube and the chamber such that liquids and gases may enter the chamber from the tube but are prevented from leaving the chamber through the one-way valve. The bulb has an external opening in which a hydrophobic filter is positioned which allows gases to escape the chamber via the external opening but prevents liquids from escaping the chamber via the external opening. The pneumostoma management device thus allows gases to pass from the lung of the patient through the pneumostoma management device and escape through the external aperture. Whereas liquids pass from the lung into the chamber where they are trapped between the one-way valve and the hydrophobic filter.

Thus, various devices and methods are provided for managing a pneumostoma. Other objects, features and advantages of the invention will be apparent from drawings and detailed description to follow.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and further features, advantages and benefits of the present invention will be apparent upon consideration of the present description taken in conjunction with the accompanying drawings.

FIG. 1A shows the chest of a patient showing a pneumostoma that may be managed using the device and methods of the present invention.

FIG. 1B shows a sectional view of the chest illustrating the relationship between the pneumostoma, lung and natural airways.

FIG. 1C shows a detailed sectional view of a pneumostoma.

FIG. 2A shows a perspective cutaway view of a pneumostoma management device according to an embodiment of the present invention.

FIG. 2B shows a sectional view of a pneumostoma management device according to an embodiment of the present invention.

FIG. 3A shows the chest of a patient illustrating placement of the pneumostoma management device according to an embodiment of the present invention.

FIG. 3B shows a sectional view of a pneumostoma illustrating placement of the pneumostoma management device according to an embodiment of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The following description is of the best modes presently contemplated for practicing various embodiments of the present invention. The description is not to be taken in a limiting sense but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be ascertained with reference to the claims. In the description of the invention that follows, like numerals or reference designators will be used to refer to like parts or elements throughout. In addition, the first digit of a reference number identifies the drawing in which the reference number first appears.

Pneumostoma Formation and Anatomy

FIG. 1A shows the chest of a patient showing a pneumostoma that may be managed using the device and methods of the present invention. Pneumostoma 110 is shown on the front of the chest 10 over the right lung (not shown). In general one pneumostoma per lung is created however, more or less than one pneumostoma per lung may be created depending upon the needs of the patient. A pneumostoma is surgically created by forming an artificial channel through the chest wall and joining that channel with an opening through the visceral membrane of the lung into parenchymal tissue of the lung to form an anastomosis. The anastomosis is preferably joined and sealed by sealing the channel to the lung using adhesions such as a pleurodesis. Methods for forming the channel, opening, anastomosis and pleurodesis or the pneumostoma are disclosed in applicant's commonly-owned, patents and patent applications including U.S. patent application Ser. No. 10/881,408, now U.S. Pat. No. 7,682,332, issued Mar. 23, 2010, entitled “Methods and Devices to Accelerate Wound Healing in Thoracic Anastomosis Applications” and U.S. Provisional Patent Application Ser. No. 60/938,466 entitled “Variable Parietal/Visceral Pleural Coupling” which are incorporated herein by reference.

FIG. 1B shows a sectional view of the chest 100 illustrating the position of the pneumostoma 110. The parenchymal tissue of the lung is comprised principally of alveoli 134. The alveoli 134 are the thin walled air-filled sacs in which gas exchange takes place. Air flows into the lungs through the natural airways including the trachea 136, carina 137, and bronchi 138. Inside the lungs, the bronchi branch into a multiplicity of smaller vessels referred to as bronchioles (not shown). Typically, there are more than one million bronchioles in each lung. Each bronchiole connects a cluster of alveoli to the natural airways. As illustrated in FIG. 1B, pneumostoma 110 comprises a channel 120 through the thoracic wall 106 of the chest 100 between the ribs 107. Channel 120 opens at an aperture 126 through the skin 114 of chest 100. The channel 120 is joined to a cavity 122 within the parenchymal tissue 132 of lung 130.

FIG. 1C shows a detailed sectional view of the pneumostoma 110. As illustrated in FIG. 1C, pneumostoma 110 comprises a channel 120 through the thoracic wall 106 of the chest 100 between the ribs 107. The channel 120 is joined to cavity 122 in the parenchymal tissue 132 of lung 130. An adhesion or pleurodesis 124 surrounds the channel 120 where it enters the lung 130. The thoracic wall 106 is lined with the parietal membrane 108. The surface of the lung 130 is covered with a continuous sac called the visceral membrane 138. The parietal membrane 108 and visceral membrane 138 are often referred to collectively as the pleural membranes. Between the parietal membrane 108 and visceral membrane 138 is the pleural cavity (pleural space) 140. The pleural cavity usually only contains a thin film of fluid that serves as a lubricant between the lungs and the chest wall. In pleurodesis 124 the pleural membranes are fused and/or adhered to one another eliminating the space between the pleural membranes in that region.

An important feature of the pneumostoma is the adhesion or pleurodesis 124 surrounding the channel 120 where it enters the lung 130. The pleurodesis 124 is the localized fusion or adhesion of the parietal membrane 108 and visceral membrane 138. The pleurodesis 124 surrounding the channel 120 prevents air from the lung 130 or channel 120 from entering the pleural cavity 140. If air is permitted to enter pleural cavity 140, a pneumothorax would result and the lung would collapse. One method for creating pleurodesis between the visceral pleura of the lung and the inner wall of the thoracic cavity uses chemical methods, including irritants such as Doxycycline and/or Bleomycin, surgical methods, including pleurectomy or thorascopic talc pleurodesis, or radiotherapy methods, including radioactive gold or external radiation. All of these methods inflames and fuse the pleural membranes. Alternatively adhesion can be created between the pleural membranes using biocompatible glues. A range of biocompatible glues are available that may be used on the lung, including light-activatable glues, fibrin glues, and two part polymerizing glues.

The pneumostoma 110 provides an extra pathway for exhaled air to exit the lung 130 without passing through the major natural airways such as the bronchi 138 and trachea 136. Collateral ventilation is the term given to leakage of air through the connective tissue between the alveoli 134. This air typically becomes trapped in the lung and contributes to hyperinflation. Collateral ventilation is particularly prevalent in an emphysemous lung because of the deterioration of lung tissue caused by COPD. In lungs that have been damaged by COPD and emphysema the resistance to flow in collateral channels (not shown) of the parenchymal tissue 132 is reduced allowing collateral ventilation to increase. By providing pneumostoma 110, air from alveoli 134 of parenchymal tissue 132 that passes into collateral pathways of lung 130 is collected in cavity 122 of pneumostoma 110. Pneumostoma 110 thus makes use of collateral ventilation to collect air in cavity 122 of pneumostoma 110 and vent the air outside the body while bypassing the natural airways which have been impaired by COPD and emphysema.

By providing this ventilation bypass, the pneumostoma allows the stale air trapped in the parenchymal tissue 132 to escape from the lung 130 and reduces the residual volume and intra-thoracic pressure. The lower intra-thoracic pressure reduces the dynamic collapse of airways during exhalation. By allowing the airways to remain patent during exhalation, labored breathing (dyspnea) and residual volume (hyperinflation) are both reduced. The pneumostoma not only provides an extra pathway that allows air to exit the lungs but also allows more fresh air to be drawn in through the natural airway and increases the effectiveness of all of the tissues of the lung improving gas exchange. The pneumostoma thus achieves many of the advantages sought by lung volume reduction surgery without surgically removing a portion of the lung or sealing off a portion of the lung.

Applicants have found that a pneumostoma management device in accordance with embodiments of the present invention is desirable to prevent the entry of foreign matter into lung 130.

Pneumostoma Management Device

FIGS. 2A and 2B illustrate a pneumostoma management device (“PMD”) 200 in accordance with an embodiment of the present invention. PMD 200 comprises an implantable sleeve 210 joined at its proximal end 211 with a bulb 220 which may be mounted to the skin of the patient. In a preferred embodiment sleeve 210 is formed in one piece with bulb 220. In preferred embodiments, sleeve 210 and bulb 220 are formed from biocompatible polymers or a biocompatible metal, for example, stainless steel.

Sleeve 210 preferably comprises a rounded distal tip 212 as shown in FIGS. 2A and 2B. Tip 212 in order to reduce irritation of damage to the tissues of the pneumostoma or lung during insertion or while in position. Sleeve 210 has an opening 214 in tip 212. Opening 214 allows the entry of gases from the cavity of the pneumostoma into sleeve 210 and thence via the lumen 218 of sleeve 210 to the bulb 220.

Bulb 220 is connected to the proximal end 211 of sleeve 210. In one embodiment, illustrated in FIGS. 2A and 2B, bulb 220 comprises a flange 222 and a dome 224. The flange 222 and dome 224 define a chamber 226. The chamber 226 has an entrance aperture 228 and at least one exit aperture 230. Exhaled air and solid material may flow from lumen 218 of sleeve 210 into chamber 226 through entrance aperture 228. Exhaled air may exit chamber 226 through exit aperture 240 to vent to atmosphere outside of the patient's body.

For simplicity of manufacturing, flange 222, and dome 224 may be formed in one piece as shown in FIG. 2B. Bulb 220 has a smooth surface and a low profile so it is comfortable for the patient to wear. Bulb 220 is designed so as not to snag on the patient's clothing or to restrict motion of the patient. Chamber 226 is sized and configured to receive liquid and/or solid material 290 such as mucous which may be exhaled from the lung through the pneumostoma 110.

Flange 222 is significantly wider than sleeve 210. Flange 222 thus comprises a contact surface 232 perpendicular to sleeve 210 and surrounding sleeve 210 which, when the sleeve 210 of PMD 200 is positioned in a pneumostoma 110, will contact the skin of the patient surrounding pneumostoma 110. The contact surface 232 serves as an insertion limit to prevent over-insertion of sleeve 210 into a pneumostoma 110. Flange 222 is designed such that it sufficiently flexible that it can conform to the skin 114 of chest 100. Contact surface 232 is also provided with a biocompatible adhesive 234, such as a hydrocolloid adhesive, for securing PMD 200 to the skin 114 of the patient. Adhesive 234 should be selected so as to help maintain the correct position of PMD 200 without causing undue irritation to the skin of the patient.

A flow control device 240 is positioned in aperture 228 between lumen 218 of sleeve 210 and chamber 226. Flow control device 240 is positioned and mounted such that material moving between lumen 218 and chamber 226 must pass through flow control device 240. In the embodiment shown in FIGS. 2A and 2B, flange 222 is provided with a recess 236 into which flow control device 240 may be mounted.

Flow control device 240 may comprise a one-way valve assembly such as a flapper valve, Heimlich valve, reed valve, or the like, for allowing air to be exhaled through entrance aperture 228 into chamber 226 while restricting the flow of air or other matter into lumen 218 from chamber 226. It is desirable to restrict flow of air in through the pneumostoma so as to encourage a reduction in hyperinflation and to prevent the inhalation of solid or liquid matter from into the lung through the pneumostoma. The flow control device 240 shown in FIG. 2B comprises a fixed disc 242 having a number of apertures 244. Above fixed disc 242 is a flapper disc 246. Flapper disc 246 is kept in place above fixed disc 242 by hinge 248. When the air pressure in lumen 218 is greater than the air pressure in chamber 226 during exhalation, flapper disc 246 moves away from fixed disc 242 and air may pass through a space between fixed disc 242 and flapper disc 246 and enter chamber 226 from lumen 218. However, when the air pressure in lumen 218 is less than the air pressure in chamber 226 during inhalation, flapper disc 246 moves towards fixed disc 242 and obstructs the apertures 244 in fixed disc 242 such that no air may pass into lumen 218 from chamber 226.

A hydrophobic filter 250 is positioned in exit aperture 230 between chamber 226 and the exterior of bulb 220. Hydrophobic filter 250 is positioned and mounted such that material moving between chamber 226 and the exterior of bulb 220 must pass through hydrophobic filter 250. Hydrophobic filter 250 prevents the flow of water in and out of chamber 226 through exit aperture 230. In the embodiment shown in FIGS. 2A and 2B, bulb 224 is provided with a recess 238 into which hydrophobic filter 250 may be press fit.

Use of the Pneumostoma Management Device

FIG. 3A illustrates the use of PMD 200 in pneumostoma 110 of FIG. 1A. As shown in FIG. 3A the low profile of PMD 200 allows it to be inconspicuously positioned on the chest 100 of a patient in the frontal 110 location. PMD 200 is designed so as not to interfere with the range or motion or clothing of the patient. This is of importance for a device such as PMD 200 which must be used continuously to be effective. Comfort and ease of use are important if patient compliance with treatment protocols is to be achieved.

FIG. 3B shows a sectional view through PMD 200 and pneumostoma 110 showing the interaction of the PMD with the pneumostoma 110. It should be noted that sleeve 210 fits snugly within channel 120 of pneumostoma 110. Sleeve 210 is sized and configured such that it penetrates through channel 120 into cavity 122 in the parenchymal tissue 132 of lung 130. Contact surface 232 of flange 222 is pushed into contact with skin 114 of the thoracic wall 106 of chest 100 thus preventing further insertion of sleeve 210. Adhesive 234 contacts skin 114 holding PMD 200 in position. Flange 222 conforms to the surface of chest 100 to secure PMD 200 to chest 100 with adhesive 234.

Because of the snug fit of sleeve 210 within channel 120 and the contact between flange 222 and/or adhesive 234 with skin 114, PMD 200 effectively controls the movement of all material in or out of the pneumostoma. From lumen 218, exhaled air flows through flow control device 240 into chamber 226 as shown by arrow 304. Any liquid and/or solid material 290 remains trapped in chamber 226. Air flows out of chamber 226 to the exterior of PMD 200 and the patient through hydrophobic filter 250 as shown by arrow 306. Thus PMD 200 allows air to exit pneumostoma 110 and vent to atmosphere while preventing the entry of water or solids into the pneumostoma 110.

The foregoing description of preferred embodiments of the present invention has been provided for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many embodiments were chosen and described in order to best explain the principles of the invention and its practical application, thereby enabling others skilled in the art to understand the invention for various embodiments and with various modifications that are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims and their equivalents.

Claims

1. A pneumostoma management device adapted to be mounted on a chest of a patient to treat a lung of a patient and control flow of liquids and gases through a pneumostoma wherein the pneumostoma management device comprises: a tube adapted to pass into the pneumostoma wherein the tube has a distal opening adapted to be positioned within the lung to allow liquids and gases to enter the tube from the lung;a bulb connected to a proximal end of the tube wherein the bulb defines a chamber;a one-way valve positioned between the distal opening of the tube and the chamber such that liquids and gases may enter the chamber from the tube and are prevented from leaving the chamber through the one-way valve;an external opening in the bulb;a hydrophobic filter positioned in the external opening which allows gases to escape the chamber via the external opening and which prevents liquids from escaping the chamber via the external opening;whereby gases may pass from the lung of the patient through the pneumostoma management device and escape through the external aperture and whereby liquids may pass from the lung into the chamber where they are trapped between the one-way valve and the hydrophobic filter.

2. The pneumostoma management device of claim 1, wherein the bulb comprises a flange substantially perpendicular to the tube and adapted to contact the chest of the patient surrounding the pneumostoma to prevent over-insertion of the tube.

3. The pneumostoma management device of claim 2, wherein the flange comprises an adhesive positioned to secure the flange to the chest of the patient.

4. The pneumostoma management device of claim 2, wherein the flange comprises a hydrocolloid adhesive positioned to secure the flange to the chest of the patient.

5. The pneumostoma management device of claim 1, wherein the flange is adapted to conform to the chest of the patient.

6. The pneumostoma management device of claim 1, wherein the one-way valve is press-fit into the bulb where the tube connects to the bulb.

7. The pneumostoma management device of claim 1, wherein the one-way valve comprises one of a reed valve, a flapper valve and a Heimlich valve.

8. The pneumostoma management device of claim 1, wherein the bulb is formed in one piece with the tube.

9. The pneumostoma management device of claim 1, wherein the hydrophobic filter is press-fit into the external opening of the bulb.

10. A medical device adapted to control movement of gases and non-gaseous discharge through a pneumostoma wherein the medical device comprises: a tube adapted to pass into the pneumostoma wherein the tube has a distal opening adapted to be positioned within the lung to allow gases and non-gaseous discharge to enter the tube from the lung;a bulb connected to a proximal end of the tube wherein the bulb defines a chamber adapted to contain the non-gaseous discharge;a valve configured such that gases and non-gaseous discharge may enter the chamber from the tube and are prevented from leaving the chamber through the tube;an external opening in the bulb;a filter positioned in the external opening which allows gases to escape the chamber via the external opening and which prevents non-gaseous discharge from escaping the chamber via the external opening;whereby gases may escape for the lung through the medical device and discharge is trapped in the chamber between the valve and the filter.

11. The medical device of claim 10, wherein the bulb comprises a contact surface substantially perpendicular to the tube and adapted to contact a chest of a patient to limit insertion of the tube into the pneumostoma.

12. The medical device of claim 10, wherein the bulb comprises a contact surface substantially perpendicular to the tube and bearing an adhesive adapted to temporarily secure the bulb to a chest of a patient.

13. The medical device of claim 10, wherein the bulb comprises a contact surface substantially perpendicular to the tube and bearing a hydrocolloid adhesive adapted to releasably secure the bulb to a chest of a patient.

14. The medical device of claim 13, wherein the contact surface is sufficiently flexible to conform to the chest of the patient.

15. The medical device of claim 10, wherein the valve comprises a valve selected from a one-way valve, a reed valve, a flapper valve and a Heimlich valve.

16. The medical device of claim 10, wherein the valve fits in a recess in the flange.

17. The medical device of claim 10, wherein the hydrophobic filter fits in a recess in the bulb.

18. The medical device of claim 10, wherein the bulb and tube are formed in one piece.

19. A medical device adapted to control movement of gases and non-gaseous discharge through a pneumostoma wherein the medical device comprises: a tube formed in one piece with a bulb wherein the bulb comprises a contact surface substantially larger in diameter than the tube and wherein the tube extends substantially perpendicular to the contact surface such that the tube is adapted to be pushed into the pneumostoma until the contact surface contacts a chest of a patient;a chamber within the bulb connected to a lumen which passes through the tube to an opening in a distal end of the tube;a valve configured to allow gases and non-gaseous discharge to enter the chamber from the lumen and prevent gases and non-gaseous discharge from leaving the chamber through the lumen;an external opening in the bulb;a filter positioned in the external opening which allows gases to escape the chamber via the external opening and which prevents non-gaseous discharge from escaping the chamber via the external opening;whereby the medical device controls movement of gases and non-gaseous discharge through the pneumostoma.

20. The medical device of claim 19, wherein the contact surface includes a biocompatible adhesive adapted to releasably secure the bulb to the chest of the patient.